SCHEMBL5677804

SCHEMBL5677804

CCc1nn(C[C@H](C)NC(=O)OC(C)(C)C)c2cc(SC)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.38
SLC22A12 Q96S37 7/20 0.36
KMT2A Q03164 1/20 0.35
GAA P10253 2/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32
SYK P43405 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
TSHR P16473 1/20 0.32
MMP13 P45452 1/20 0.32
CTSK P43235 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677813 1.00 BRD4 (0.38) BRD4SLC22A12KMT2AGAAALDH1A1
SCHEMBL5679757 0.89 AAK1 (0.41) SLC22A12ALDH1A1MAPTCTSK
SCHEMBL5679751 0.89 AAK1 (0.41) SLC22A12ALDH1A1MAPTCTSK
SCHEMBL5678090 0.88 BRD4 (0.37) BRD4SLC22A12KMT2AALDH1A1MAPT
SCHEMBL5678084 0.88 BRD4 (0.37) BRD4SLC22A12KMT2AALDH1A1MAPT
SCHEMBL5679817 0.86 PPARG (0.36) SLC22A12
SCHEMBL5679829 0.86 PPARG (0.36) SLC22A12
SCHEMBL5679666 0.75 DYRK1A (0.46) BRD4SLC22A12KMT2AALDH1A1KDM4E
SCHEMBL5679657 0.75 DYRK1A (0.46) BRD4SLC22A12KMT2AALDH1A1KDM4E
SCHEMBL5678047 0.73 GLS (0.43) BRD4KMT2AGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1129078-B1 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RES LTD (GB) 2006-03-15 EP disclosed
US-6552062-B1 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity VERNALIS RESEARCH LIMITED (GB) 2003-04-22 US disclosed